NCT04023721 - Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2019

Primary Completion Date

July 16, 2020

Study Completion Date

July 16, 2020

Conditions

Hepatitis BHBVHepatitis B, Chronic

Interventions

DRUG

Inarigivir soproxil

Inarigivir soproxil 200 mg tablets

DRUG

Nucleoside/nucleotide (NUC) analogue inhibitors

Continuation of prestudy NUC therapy

Trial Locations (7)

University of Calgary, Calgary

GI Research Institute, Vancouver

LAIR Centre, Vancouver

Toronto General Hospital, Toronto

Toronto Liver Center, Toronto

Barts Health NHS Trust, London

King's College Hospital NHS Foundation Trust, London